Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Esperion Therapeutics Inc | ESPR | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 2.10 | 03:06:30 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 2.10 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.70 - 3.40 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 2.10 | USD |
Esperion Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 388.61M | 185.05M | - | 116.33M | -209.25M | -1.13 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Esperion Therapeutics News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ESPR Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.44 | 2.63 | 2.06 | 2.24 | 5,999,697 | -0.34 | -13.93% |
| 1 Month | 1.99 | 2.63 | 1.94 | 2.28 | 8,759,720 | 0.11 | 5.53% |
| 3 Months | 2.41 | 3.40 | 1.71 | 2.40 | 7,724,835 | -0.31 | -12.86% |
| 6 Months | 1.22 | 3.40 | 1.19 | 2.35 | 6,914,967 | 0.88 | 72.13% |
| 1 Year | 1.50 | 3.40 | 0.70 | 1.99 | 5,134,559 | 0.60 | 40.00% |
| 3 Years | 19.85 | 26.77 | 0.70 | 3.49 | 2,858,427 | -17.75 | -89.42% |
| 5 Years | 49.36 | 79.989 | 0.70 | 8.05 | 1,958,429 | -47.26 | -95.75% |
Esperion Therapeutics Description
| Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. |
